We are live on ! Find out more
SLS icon

SELLAS Life Sciences
SLS

11 hedge funds and large institutions have $3.7M invested in SELLAS Life Sciences in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

0.06% less ownership

Funds ownership: 0.38% → 0.31% (-0.06%)

27% less capital invested

Capital invested by funds: $5.1M → $3.7M (-$1.4M)

45% less funds holding

Funds holding: 20 → 11 (-9)

90% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 10

Holders
11
Holders Change
-9
Holders Change %
-45%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
4
Closed
10
Calls
$64K
Puts
–
Net Calls
+$64K
Net Calls Change
-$98K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$155K
2
Renaissance Technologies
Renaissance Technologies
New York
+$138K
3
TSS
Two Sigma Securities
New York
+$15K
4
Northern Trust
Northern Trust
Illinois
+$5.49K
5
Morgan Stanley
Morgan Stanley
New York
+$1.88K

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$869K
2
OAM
Oxford Asset Management
United Kingdom
-$72K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$35K
4
Citadel Advisors
Citadel Advisors
Florida
-$21K
5
WS
Wedbush Securities
California
-$12K

SLS Hedge Fund Activity: Q1 2019 in Review

11 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q1 2019, worth a combined $3.7M — down 27% from $5.1M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of SLS and 1 opened new positions — a net loss of 9 holders — while 4 trimmed existing stakes and 4 added.

The largest buyer was Vanguard Group, adding an estimated $155K. The largest seller was 683 Capital Management, cutting an estimated $869K.

  • 11 institutional investors held SELLAS Life Sciences (SLS) as of Q1 2019, down from 20 in Q4 2018.
  • Funds reported $3.7M of SELLAS Life Sciences stock for Q1 2019, down 27% quarter-over-quarter.
  • 1 fund opened new SELLAS Life Sciences positions in Q1 2019 and 10 closed out, a net change of -9 holders.
  • The largest SELLAS Life Sciences buyer in Q1 2019 was Vanguard Group, an estimated $155K added.
  • The largest SELLAS Life Sciences seller in Q1 2019 was 683 Capital Management, an estimated $869K sold.

Based on aggregated 13F filings for Q1 2019.